MDGLMEDIUM SIGNALFINANCIAL10-K

MDGL showed meaningful operational improvement with substantially reduced losses while building commercial capabilities following Rezdiffra's regulatory approval.

The company appears to be transitioning from pure development to commercialization, evidenced by the substantial expansion in SG&A expenses alongside meaningfully improved operating performance. The language changes emphasize post-marketing commitments and reimbursement challenges, indicating focus has shifted to commercial execution risks rather than development uncertainties.

Comparing 2026-02-19 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

MDGL's financial position reflects a company in commercial transition, with cash nearly doubling to $199M while current liabilities grew substantially, likely reflecting increased commercial infrastructure investments. Operating losses improved meaningfully alongside a substantial expansion in SG&A expenses, suggesting increased commercial spending is beginning to drive operational efficiency. The overall picture signals a biotech company moving from development losses toward potential profitability, though cash burn remains significant despite improvement.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+98.7%
$100.0M→$198.7M

Cash position surged 98.7% — strong cash generation or capital raise providing significant financial cushion.

SG&A Expense
P&L
+87.1%
$435.1M→$813.8M

SG&A up 87.1% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Current Liabilities
Balance Sheet
+83.3%
$169.3M→$310.3M

Current liabilities surged 83.3% — significant near-term obligations; verify ability to meet short-term debt.

Capital Expenditure
Cash Flow
-68.1%
$1.5M→$467K

Capex reduced 68.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+58.4%
-$455.6M→-$189.6M

Operating cash flow surged 58.4% — exceptional cash generation, highest quality earnings signal.

Operating Income
P&L
+39.7%
-$497.9M→-$300.1M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+38.1%
-$465.9M→-$288.3M

Net income grew 38.1% — bottom-line growth signals improving overall business health.

Total Assets
Balance Sheet
+20.9%
$1.0B→$1.3B

Asset base grew 20.9% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+20.6%
$1.0B→$1.2B

Current assets grew 20.6% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
-20.1%
$754.4M→$602.7M

Equity decreased 20.1% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-02-19
PRIOR — 2025-02-26
ADDED
As of February 12, 2026, the registrant had 22,939,969 shares of common stock outstanding.
You should not place undue reliance on any such forward-looking statements.
You should carefully consider all of the information in this report and, in particular, the following principal risks and all of the other specific factors described in Item 1A.
of this report, Risk Factors, before deciding whether to invest in our company.
We obtained accelerated approval in the United States and conditional marketing authorization in the European Union ( EU ) for Rezdiffra, and we are subject to certain post-marketing commitments.
If we are unable to obtain or maintain adequate coverage and reimbursement from government or third-party payors for Rezdiffra or, if approved, any other product candidates, our prospects for generating revenue may be adversely affected.
Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact our product revenues and materially harm our business.
Rezdiffra remains subject to ongoing regulatory review, and if we fail to comply with regulations or satisfy our post-approval commitments, we could lose our approval and the sale of Rezdiffra could be suspended.
Rezdiffra was approved for treatment in a limited population of patients with MASH with moderate to advance liver fibrosis, and additional clinical trials and regulatory applications are required to expand its indication.
We may not be successful in obtaining such regulatory approval to expand Rezdiffra s indication.
REMOVED
As of February 21, 2025, the registrant had 22,080,246 shares of common stock outstanding.
You should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made.
Before you invest in our securities, you should read the following summary together with the more detailed description of material risks described in the section titled Risk Factors in Part I, Item 1A of this Annual Report and the other information contained in this Annual Report.
We obtained regulatory approval of Rezdiffra in the United States through an accelerated approval process, and we are subject to certain post-marketing commitments.
We may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.
The pricing of pharmaceutical products has come under increasing scrutiny as part of a global trend toward healthcare cost containment.
Rezdiffra remains subject to ongoing regulatory review, and if we fail to comply with continuing regulations, we could lose our approval and the sale of Rezdiffra could be suspended.
We may never obtain approval or commercialize Rezdiffra outside of the United States, which would limit our ability to realize its full market potential.
Governments outside of the United States tend to impose strict price controls, which may adversely affect our revenues, if any.
If clinical trials or regulatory approval processes are prolonged, delayed or suspended, we may be unable to advance the development of or commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any revenue from potential product sales.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →